Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC raised its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 109.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 254,647 shares of the company's stock after buying an additional 132,817 shares during the quarter. Jane Street Group LLC's holdings in Takeda Pharmaceutical were worth $3,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at approximately $52,000. Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical during the 4th quarter worth about $61,000. Venturi Wealth Management LLC boosted its holdings in Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC grew its position in shares of Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after buying an additional 2,029 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded up $0.11 on Friday, reaching $14.11. The company's stock had a trading volume of 1,136,705 shares, compared to its average volume of 1,911,866. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.43. The stock has a market capitalization of $44.88 billion, a P/E ratio of 35.26, a PEG ratio of 0.24 and a beta of 0.26. The stock's 50-day moving average is $14.78 and its two-hundred day moving average is $14.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.